Dutch survey found wide variation in radiotherapy for unresectable recurrent rectal cancer
Dutch radiation oncologists reported substantial variation in dose, delineation, and follow-up for unresectable locally recurrent rectal cancer.
Dutch radiation oncologists reported substantial variation in dose, delineation, and follow-up for unresectable locally recurrent rectal cancer.
Pencil-beam scanning proton re-irradiation achieved 17.2-month median survival with 7.7% grade 3 or higher oral mucositis.
Gamma Knife radiosurgery achieved 73.53% 5-year progression-free survival in a small postoperative papillary craniopharyngioma cohort.
Surface-guided radiotherapy kept mean setup shifts near zero during frog-leg vulvar volumetric modulated arc therapy.
Thermo-optical surface monitoring with X-ray correction kept breast deep inspiration breath-hold setup errors within clinical tolerance.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
Adding pan-mucosal irradiation did not improve survival or reduce mucosal recurrence compared with nodal-only irradiation in thoroughly staged head and neck unknown primary cancer.
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Four-year overall survival was 81.2%, and starting proton therapy at week 14 or later was not independently associated with worse outcomes.
Carbon ion radiotherapy achieved 82.9% two-year locoregional control, while combined immunotherapy was associated with longer overall survival.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.